Title:MicroRNAs and their Implications in CD4+ T-cells,
Oligodendrocytes and Dendritic Cells in Multiple Sclerosis
Pathogenesis
Volume: 23
Issue: 7
Author(s): Armin Safari*, Soheil Madadi*, Heidi Schwarzenbach, Mohsen Soleimani, Armita Safari, Mohammad Ahmadi and Meysam Soleimani*
Affiliation:
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical
Sciences, Hamadan, Iran
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical
Sciences, Hamadan, Iran
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
Keywords:
Oligodendrocytes, Th1 cells, T-regulatory cells, Th17 cells, dendritic cells, microRNAs.
Abstract: MicroRNAs (miRNAs) have been established as key players in various
biological processes regulating differentiation, proliferation, inflammation, and
autoimmune disorders. Emerging evidence suggests the critical role of miRNAs in the
pathogenesis of multiple sclerosis (MS). Here, we provide a comprehensive overview of
miRNAs, which are differentially expressed in MS patients or experimental autoimmune
encephalomyelitis (EAE) mice and contribute to MS pathogenesis through regulating
diverse pathways, including CD4+ T cells proliferation, differentiation, and activation in
three subtypes of CD4+ T cells, including Th1, Th17 and regulatory T cells (Tregs).
Moreover, the regulation of oligodendrocyte precursor cells (OPC) differentiation as a
crucial player in MS pathogenesis is also described. Our literature research showed that
miR-223 could affect different pathways involved in MS pathogenesis, such as
promoting Th1 differentiation, activating the M2 phenotype of myeloid cells, and clearing
myelin debris. MiR-223 was also identified as a potential biomarker, distinguishing
relapsing-remitting multiple sclerosis (RRMS) from progressive multiple sclerosis (PMS),
and thus, it may serve as an attractive target for further investigations. Our overview
provides novel potential therapeutic targets for the treatment and new insights into
miRNAs' role in MS pathogenesis.